Proteomic differentiation of leukemia cells based on multiplexed arrays and mass

基于多重阵列和质量的白血病细胞的蛋白质组分化

• 批准号: 8451922
• 负责人: W. Andy Tao
• 金额: $ 30万
• 依托单位: TYMORA ANALYTICAL OPERATIONS, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-16 至 2015-09-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8451922
• 关键词: Acute Lymphocytic Leukemia; Address; Affinity; Antibodies; Antibody Specificity; Behavior; Biological Assay; Biological Markers; Biomedical Research; Cell Line; Cells; Classification; Clinical; Data Set; Detection; Development; Diagnosis; Diagnostic tests; Disease; Disease Management; Disseminated Malignant Neoplasm; Flow Cytometry; Gene Mutation; Genes; Global Change; Goals; Hematologic Neoplasms; Human; Hybrids; Immunohistochemistry; Immunophenotyping; Individual; Ions; Lead; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Measures; Molecular; Monitor; Mutation; Oncogenic; Pathway interactions; Peptides; Pharmaceutical Preparations; Phase; Phospho-Specific Antibodies; Phosphopeptides; Phosphorylation; Phosphorylation Site; Phosphotransferases; Post-Translational Protein Processing; Process; Property; Proteins; Proteomics; Reagent; Reporting; Research Personnel; Resolution; Sampling; Signal Pathway; Small Business Technology Transfer Research; Specificity; Staging; Techniques; Technology; Testing; United States National Institutes of Health; Water; anticancer research; base; cancer cell; cancer diagnosis; cancer type; combat; cost; data acquisition; disorder subtype; fluorophore; innovation; innovative technologies; inorganic phosphate; leukemia; nanopolymer; neoplastic cell; novel; phase 1 study; phase 2 study; prototype; public health relevance; research and development; research study; response; success; therapeutic target; tool

DESCRIPTION (provided by applicant): Although some gene mutations can predict response to certain targeted therapies, single-gene testing has limits. Multiple important signaling pathways that may be the causes of human malignancy have continuously been discovered and dissected. Pathway and network diagnostic tests are challenging but are clearly on the way. Through this NIH STTR Phase I study, we will develop a hybrid phosphoproteomic platform to differentiate leukemia at the molecular level. The platform features two innovative products recently introduced by us which are based on multi-functionalized water-soluble nanopolymers, allowing for highly selective, sensitive and simple qualitative and quantitative assessment of protein phosphorylation without the use of expensive phosphospecific antibodies. Due to its size and unique properties, it also offers the capability for multiplexed detection of phosphorylation and total protein amount simultaneously. Combined with targeted mass spectrometric analysis, this hybrid platform will be a powerful tool for biomedical research and development, particularly in the field of leukemia treatment, and a potential clinical tool for cancer diagnosis.

描述（由申请人提供）：虽然一些基因突变可以预测对某些靶向治疗的反应，但单基因检测具有局限性。可能导致人类恶性肿瘤的多种重要信号通路不断被发现和剖析。通路和网络诊断测试具有挑战性，但显然正在进行中。通过这项NIH STTR I期研究，我们将开发一个混合磷酸蛋白质组学平台，在分子水平上区分白血病。该平台具有我们最近推出的两种创新产品，它们基于多功能化的水溶性纳米聚合物，可以在不使用昂贵的磷酸特异性抗体的情况下，对蛋白质磷酸化进行高度选择性，灵敏度和简单的定性和定量评估。由于其尺寸和独特的性质，它还提供了同时多重检测磷酸化和总蛋白量的能力。结合靶向质谱分析，这种混合平台将成为生物医学研究和开发的有力工具，特别是在白血病治疗领域，以及癌症诊断的潜在临床工具。